BioCurie Secures $9.3M ARPA-H Award to Develop AI-Powered Gene Therapy Manufacturing Platform
核心洞察
BioCurie (搜索) received up to $9.3 million from ARPA-H (搜索) to develop an AI-driven digital platform that replaces trial-and-error bioprocess development with computational modeling for gene therapy (搜索) manufacturing.
The platform aims to address persistent manufacturing bottlenecks in gene therapy (搜索) by integrating machine learning with real-world manufacturing data to reduce development timelines and improve process robustness.
The project involves a consortium including St. Jude Children's Research Hospital and Center for Breakthrough Medicines (搜索), targeting both viral and non-viral gene therapy (搜索) production scalability.
BioCurie (搜索), a Delaware and Cambridge-based TechBio company, has secured up to $9.3 million from the Advanced Research Projects Agency for Health (ARPA-H (搜索)) to develop an AI-powered digital platform for cell and gene therapy (搜索) manufacturing. The award addresses one of the most significant bottlenecks in bringing gene therapies to patients: manufacturing challenges that continue to slow commercialization despite transformative clinical results.
Manufacturing Bottlenecks Drive Innovation Need
High development costs, unpredictable yields, and lengthy process optimization cycles have persistently limited patient access across the gene therapy (搜索) industry. Traditional trial-and-error approaches to bioprocess development have proven insufficient for the scalable production demands of genomic medicines (搜索), creating an urgent need for more sophisticated manufacturing solutions.
Under the ARPA-H (搜索) award, BioCurie (搜索) will design, build, and validate an AI-powered digital platform intended to replace conventional process development methods. The platform integrates advanced computational modeling, machine learning, and real-world manufacturing data to shorten development timelines and improve process robustness across both viral and non-viral gene therapy (搜索) production.
Cross-Sector Consortium Approach
The project brings together a strategic consortium spanning academia and industry, with BioCurie (搜索) serving as the lead organization. Key partners include Caring Cross (搜索), St. Jude Children's Research Hospital, and the Center for Breakthrough Medicines (搜索) (SK pharmteco (搜索)). The University City Science Center (搜索) provided strategic support for the proposal, helping align consortium partners and federal funding strategy.
"BioCurie (搜索)'s vision for applying AI to gene therapy (搜索) manufacturing represents the kind of translational innovation ARPA-H (搜索) is designed to accelerate. We're proud to support the team as they advance this important work," said Heath Naquin, SVP of Innovation & New Ventures at University City Science Center (搜索).
Platform Design and Target Market
BioCurie (搜索)'s platform is designed to serve biopharmaceutical developers and contract manufacturing organizations (CMOs) seeking to de-risk process development, reduce costs, and scale production more predictably. The company describes itself as building the "AI infrastructure layer for genomic medicine manufacturing," combining expertise in advanced modeling, machine learning, and bioprocess engineering.
"AI will fundamentally reshape how advanced therapies are developed and manufactured. This ARPA-H (搜索) award validates our vision and accelerates our ability to deliver a scalable, digital-first manufacturing platform to therapy developers and manufacturers," said Irene Rombel, CEO of BioCurie (搜索) and Principal Investigator on the project.
Company Growth and Mission
The award follows continued growth for BioCurie (搜索) in 2025, including team expansion across its Delaware and Cambridge locations and advancement of commercial partnerships across the cell and gene therapy (搜索) ecosystem. ARPA-H (搜索) Program Manager Daria Fedyukina, Ph.D. leads the project for the agency.
Founded by Irene Rombel and Richard Braatz, BioCurie (搜索) has positioned itself at the intersection of artificial intelligence and genomic medicine manufacturing. Rombel framed the award as both validation of the company's approach and commitment to its core mission of bringing "disease-modifying and curative genomic medicines (搜索) to patients faster and more affordably."
The platform aims to enable data-driven decision-making across gene therapy (搜索) development and production, potentially transforming how the industry approaches manufacturing scalability and cost-effectiveness in genomic medicine delivery.